Page last updated: 2024-11-02

pirenzepine and Adrenal Cancer

pirenzepine has been researched along with Adrenal Cancer in 2 studies

Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Takashima, A1
Kenimer, JG1
Michel, AD1
Stefanich, E1
Whiting, RL1

Other Studies

2 other studies available for pirenzepine and Adrenal Cancer

ArticleYear
Muscarinic-stimulated norepinephrine release and phosphoinositide hydrolysis in PC12 cells are independent events.
    The Journal of biological chemistry, 1989, Jun-25, Volume: 264, Issue:18

    Topics: Adrenal Gland Neoplasms; Animals; Atropine; Cell Line; Diamines; Hydrolysis; Kinetics; Methacholine

1989
PC12 phaeochromocytoma cells contain an atypical muscarinic receptor binding site.
    British journal of pharmacology, 1989, Volume: 97, Issue:3

    Topics: Adrenal Gland Neoplasms; Animals; Binding, Competitive; Cell Membrane; Kinetics; Myocardium; N-Methy

1989